Excess Antibiotic Treatment Duration and Adverse Events in Patients Hospitalized With Pneumonia: A Multihospital Cohort Study
- PMID: 31284301
- DOI: 10.7326/M18-3640
Excess Antibiotic Treatment Duration and Adverse Events in Patients Hospitalized With Pneumonia: A Multihospital Cohort Study
Abstract
Background: Randomized trials demonstrate no benefit from antibiotic treatment exceeding the shortest effective duration.
Objective: To examine predictors and outcomes associated with excess duration of antibiotic treatment.
Design: Retrospective cohort study.
Setting: 43 hospitals in the Michigan Hospital Medicine Safety Consortium.
Patients: 6481 general care medical patients with pneumonia.
Measurements: The primary outcome was the rate of excess antibiotic treatment duration (excess days per 30-day period). Excess days were calculated by subtracting each patient's shortest effective (expected) treatment duration (based on time to clinical stability, pathogen, and pneumonia classification [community-acquired vs. health care-associated]) from the actual duration. Negative binomial generalized estimating equations (GEEs) were used to calculate rate ratios to assess predictors of 30-day rates of excess duration. Patient outcomes, assessed at 30 days via the medical record and telephone calls, were evaluated using logit GEEs that adjusted for patient characteristics and probability of treatment.
Results: Two thirds (67.8% [4391 of 6481]) of patients received excess antibiotic therapy. Antibiotics prescribed at discharge accounted for 93.2% of excess duration. Patients who had respiratory cultures or nonculture diagnostic testing, had a longer stay, received a high-risk antibiotic in the prior 90 days, had community-acquired pneumonia, or did not have a total antibiotic treatment duration documented at discharge were more likely to receive excess treatment. Excess treatment was not associated with lower rates of any adverse outcomes, including death, readmission, emergency department visit, or Clostridioides difficile infection. Each excess day of treatment was associated with a 5% increase in the odds of antibiotic-associated adverse events reported by patients after discharge.
Limitation: Retrospective design; not all patients could be contacted to report 30-day outcomes.
Conclusion: Patients hospitalized with pneumonia often receive excess antibiotic therapy. Excess antibiotic treatment was associated with patient-reported adverse events. Future interventions should focus on whether reducing excess treatment and improving documentation at discharge improves outcomes.
Primary funding source: Blue Cross Blue Shield of Michigan (BCBSM) and Blue Care Network as part of the BCBSM Value Partnerships program.
Comment in
-
Duration of Antibiotic Therapy: Shorter Is Better.Ann Intern Med. 2019 Aug 6;171(3):210-211. doi: 10.7326/M19-1509. Epub 2019 Jul 9. Ann Intern Med. 2019. PMID: 31284302 Free PMC article. No abstract available.
-
Quality and safety in the literature: January 2020.BMJ Qual Saf. 2020 Jan;29(1):86-90. doi: 10.1136/bmjqs-2019-010547. Epub 2019 Nov 20. BMJ Qual Saf. 2020. PMID: 31748401 No abstract available.
Similar articles
-
Inappropriate Diagnosis of Pneumonia Among Hospitalized Adults.JAMA Intern Med. 2024 May 1;184(5):548-556. doi: 10.1001/jamainternmed.2024.0077. JAMA Intern Med. 2024. PMID: 38526476 Free PMC article.
-
Effect of a 3-step critical pathway to reduce duration of intravenous antibiotic therapy and length of stay in community-acquired pneumonia: a randomized controlled trial.Arch Intern Med. 2012 Jun 25;172(12):922-8. doi: 10.1001/archinternmed.2012.1690. Arch Intern Med. 2012. PMID: 22732747 Clinical Trial.
-
Duration of Antibiotic Treatment in Community-Acquired Pneumonia: A Multicenter Randomized Clinical Trial.JAMA Intern Med. 2016 Sep 1;176(9):1257-65. doi: 10.1001/jamainternmed.2016.3633. JAMA Intern Med. 2016. PMID: 27455166 Clinical Trial.
-
Total duration of antimicrobial therapy in veterans hospitalized with uncomplicated pneumonia: Results of a national medication utilization evaluation.J Hosp Med. 2016 Dec;11(12):832-839. doi: 10.1002/jhm.2648. Epub 2016 Aug 16. J Hosp Med. 2016. PMID: 27527659 Review.
-
Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections.Evid Based Child Health. 2013 Jul;8(4):1297-371. doi: 10.1002/ebch.1927. Evid Based Child Health. 2013. PMID: 23877944 Review.
Cited by
-
Determinants of non-adherence to antibiotic treatment guidelines in hospitalized adults with suspected community-acquired pneumonia: a prospective study.Antimicrob Resist Infect Control. 2024 Nov 23;13(1):140. doi: 10.1186/s13756-024-01494-2. Antimicrob Resist Infect Control. 2024. PMID: 39580437 Free PMC article. Clinical Trial.
-
The Short-Term Impact of Educational Programs on Knowledge and Attitudes Regarding Antimicrobial Stewardship among Veterinary Students in Serbia.Animals (Basel). 2024 Sep 21;14(18):2736. doi: 10.3390/ani14182736. Animals (Basel). 2024. PMID: 39335325 Free PMC article.
-
Comparison of targeted next-generation sequencing and metagenomic next-generation sequencing in the identification of pathogens in pneumonia after congenital heart surgery: a comparative diagnostic accuracy study.Ital J Pediatr. 2024 Sep 12;50(1):174. doi: 10.1186/s13052-024-01749-z. Ital J Pediatr. 2024. PMID: 39267108 Free PMC article.
-
Biomarker guided antibiotic stewardship in community acquired pneumonia: A randomized controlled trial.PLoS One. 2024 Aug 20;19(8):e0307193. doi: 10.1371/journal.pone.0307193. eCollection 2024. PLoS One. 2024. PMID: 39163362 Free PMC article. Clinical Trial.
-
Multiplex real-time PCR in non-invasive respiratory samples to reduce antibiotic use in community-acquired pneumonia: a randomised trial.Nat Commun. 2024 Aug 17;15(1):7098. doi: 10.1038/s41467-024-51547-8. Nat Commun. 2024. PMID: 39154071 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical